Kite Pharma Inc. presented the latest data from a trial of KTE-C19 in non-Hodgkin lymphoma as further evidence of strong efficacy for the chimeric antigen receptor T-cell (CAR-T) therapy. But the new data, which reflect product manufactured with Kite's new process, show higher rates of some side effects.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?